Affordable Access

deepdyve-link
Publisher Website

Pretreatment Levels of Chromogranin A and Neuron-specific Enolase in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia

Authors
  • KEČKÉŠ, ŠTEFAN1, 2
  • PALAJ, JÚLIUS3
  • WACZULÍKOVÁ, IVETA4
  • DYTTERT, DANIEL3
  • MOJTOVÁ, EMÍLIA5
  • KOVÁČ, GUSTÁV6
  • DURDÍK, ŠTEFAN2, 3
  • 1 Department of Hematology and Transfusiology, St. Elizabeth Cancer Institute, Bratislava, Slovak Republic
  • 2 St. Elizabeth University of Health and Social Sciences, Bratislava, Slovak Republic
  • 3 Department of Oncological Surgery, St. Elizabeth Cancer Institute, and Faculty of Medicine in Bratislava of the Comenius University, Bratislava, Slovak Republic
  • 4 Department of Nuclear Physics and Biophysics, Faculty of Mathematics, Physics and Informatics, Comenius University, Bratislava, Slovak Republic
  • 5 Department of Endocrinology, St. Elizabeth Cancer Institute, Bratislava, Slovak Republic
  • 6 Department of Clinical Chemistry, Biochemistry and Laboratory Medicine, Slovak Medical University, Faculty of Medicine, Bratislava, Slovak Republic
Type
Published Article
Journal
In Vivo
Publisher
International Institute of Anticancer Research
Publication Date
Sep 03, 2021
Volume
35
Issue
5
Pages
2863–2868
Identifiers
DOI: 10.21873/invivo.12574
PMID: 34410979
PMCID: PMC8408706
Source
PubMed Central
Keywords
Disciplines
  • Research Article
License
Unknown

Abstract

Background/Aim: Chromogranin A (CgA) and neuron-specific enolase (NSE) are applied in the diagnosis of neuroendocrine neoplasms (NENs), especially non-functional ones. The aim of this study was to investigate the predictive values of CgA and NSE in long-term survival. Patients and Methods: Our retrospective analysis included 65 patients with histologically verified gastroenteropancreatic NEN between 2005 and 2019. We performed bivariate and multivariable analyses to evaluate the relationship between CgA and NSE values before histological assessment and overall survival. Distribution of time-to-event was analyzed using Kaplan-Meier survival curves and modelled by Cox regression models. Results: Elevated NSE levels prior to histology were significantly associated with worse survival (HR=1.13, p=0.004) and were associated with low-differentiated NENs (rs=0.321, p=0.0338). CgA was associated with well-differentiated tumors (rs=0.233), but not significantly. Conclusion: Pretreatment serum levels of NSE can serve as a valuable additional predictor of long-term survival in patients with NEN.

Report this publication

Statistics

Seen <100 times